FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
The FDA's announcement confirms full approval for dostarlimab-gxly in mismatch repair deficient endometrial cancer, as of the posted record.
The FDA has announced regular approval of dostarlimab-gxly for patients with mismatch repair deficient (dMMR) endometrial cancer, according to the agency's posted record. FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer.1
The source provided is limited to this headline-level announcement and does not include further details such as the specific indication language, dosing regimen, trial data supporting the approval, or whether this approval follows any prior regulatory designation for the drug. No information is available in the record regarding accelerated approval status, conversion from a prior approval pathway, or supporting clinical trial results.
Readers seeking the clinical trial data, dosing information, or full prescribing details behind this approval should consult the FDA's full approval documentation or the drug's label, as this record does not provide those specifics.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.